Daxor Corporation to Host Investor Conference Call to Discuss Fiscal Year 2024 Financial Results and Provide a Corporate Update on March 6, 2025

Rhea-AI Summary

Daxor (Nasdaq: DXR), the global leader in blood volume measurement technology, has scheduled an investor conference call for Thursday, March 6, 2025, at 4:30 p.m. ET. During the call, President and CEO Michael Feldschuh and CFO Robert Michel will present the company's fiscal year 2024 financial results and provide updates on corporate developments. The event will include a Q&A session, with investors having the option to submit questions in advance via email. A webcast replay will be available on Daxor.com following the call.

Oak Ridge, TN, March 04, 2025 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, today announces it will host an investor conference call on Thursday, March 6, 2025, at 4:30 p.m. ET.

President and CEO Michael Feldschuh and CFO Robert Michel will review financial results and provide an update on corporate developments. After Management’s presentation, there will be an opportunity for Q&A. Investors are encouraged to submit questions in advance via email to: info@daxor.com.

To participate, register HERE.

A webcast replay of the call will be available on the Company’s website at Daxor.com.

About Daxor Corporation

Daxor Corporation (Nasdaq: DXR), is the global leader in blood volume measurement technology focused on blood volume testing innovation. We developed and market the BVA-100^™ (Blood Volume Analyzer), the only diagnostic blood test cleared by the FDA to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms. Over 65,000+ tests have been performed at leading hospital centers across the U.S., enhancing hospital performance metrics in a broad range of surgical and medical conditions, including significantly reducing mortality and readmissions in heart failure and critical care. Daxor has several ongoing trials in the areas of heart failure treatment with support from the NIH and is under contract developing analyzers to improve combat casualty care with the U.S. Department of Defense. Daxor's mission is to advance healthcare by enabling optimal fluid management with blood volume analysis. Daxor’s vision is optimal blood volume for all. For more information, please visit our website at Daxor.com. Sign up to receive news on Daxor’s innovative technology HERE.

Forward-Looking Statements

Certain statements in this release may include forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including without limitation, statements regarding the impact of hiring sales staff and expansion of our distribution channels. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this release, including, without limitation, those risk associated with our post-market clinical data collection activities, benefits of our products to patients, our expectations with respect to product development and commercialization efforts, our ability to increase market and physician acceptance of our products, potentially competitive product offerings, intellectual property protection, FDA regulatory actions, our ability to integrate acquired businesses, our expectations regarding anticipated synergies with and benefits from acquired businesses, and additional other risks and uncertainties described in our filings with the SEC. Forward-looking statements speak only as of the date when made. Daxor does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Investor Relations Contact:
Bret Shapiro
Sr. Managing Partner, CORE IR
1-516-222-2560
brets@coreir.com

FAQ

When is Daxor (DXR) releasing its fiscal year 2024 earnings?

Daxor will discuss FY2024 results on March 6, 2025, at 4:30 p.m. ET via investor conference call.

How can investors participate in DXR's upcoming earnings call?

Investors must register through the provided link and can submit questions in advance via email to info@daxor.com.

Will there be a replay available for Daxor's (DXR) FY2024 earnings call?

Yes, a webcast replay will be available on Daxor.com after the call.

Who will be presenting at DXR's fiscal year 2024 earnings call?

CEO Michael Feldschuh and CFO Robert Michel will present the results and corporate updates.